NCT06737081View on ClinicalTrials.gov

SAL-0951 in the Treatment of Chemotherapy-induced Anemia in Patients With Non-myeloid Malignancies

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

September 14, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

June 30, 2026

Conditions
Anemia
Interventions
DRUG

SAL-0951 tablets 4mg

initial phase：4mg QD subsequent phase：1mg～8mg QD，adjust the dose based on hemoglobin concentration level every 4 weeks

DRUG

SAL-0951 tablets 5mg

initial phase：5mg QD subsequent phase：1mg～8mg QD，adjust the dose based on hemoglobin concentration level every 4 weeks

Trial Locations (1)

200030

RECRUITING

Shanghai Chest Hospital, Shanghai

All Listed Sponsors
lead

Shenzhen Salubris Pharmaceuticals Co., Ltd.

INDUSTRY